X
<

How Celgene Is Positioned after 2Q17

PART:
1 2 3 4 5 6 7 8
Part 7
How Celgene Is Positioned after 2Q17 PART 7 OF 8

Ozanimod Could Drive Celgene’s Long-Term Growth

About Ozanimod

Ozanimod is a selective sphingosine 1-phosphate 1 (or S1PR1) and 5 (or S1PR5) receptor modulator in the investigation for its efficacy and safety in the treatment of relapsing multiple sclerosis, ulcerative colitis, and Crohn’s disease.

Ozanimod Could Drive Celgene’s Long-Term Growth

Interested in CELG? Don't miss the next report.

Receive e-mail alerts for new research on CELG

Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success! has been added to your Ticker Alerts.

Success! has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

SUNBEAM and RADIANCE trial

In February 2017, Celgene (CELG) presented results from its Phase 3 SUNBEAM trial. This trial was conducted to evaluate the efficacy and safety of ozanimod for the treatment of individuals with relapsing multiple sclerosis (or RMS).

The Phase 3 SUNBEAM trial assessed the safety and efficacy of ozanimod 0.5 mg and ozanimod 1 mg compared to intramuscular interferon beta-1a (Avonex) for at least a 12-month therapy period. The study included 1,346 RMS patients and was based in 20 countries.

The data from the Phase 3 SUNBEAM trial demonstrate that both ozanimod 0.5 mg and ozanimod 1 mg therapy arms showed statistically substantial and clinically meaningful progress compared to Avonex for the primary endpoint of reducing annualized relapse rate (or ARR). The safety and tolerability data from the SUNBEAM trial remained consistent with the previously reported long-term results from the Phase 2 RADIANCE trial.

In May 2017, Celgene announced positive results from the Phase 3 RADIANCE trial. Celgene conducted the Phase 3 pivotal RADIANCE trial for evaluation of the safety and efficacy of oral ozanimod in individuals with RMS. The RADIANCE trial met its primary endpoint of reducing ARR compared to Avonex.

The Phase 3 RADIANCE trial enrolled 1,313 RMS patients and conducted the trial in 21 countries. The ozanimod 0.5mg and ozanimod 1 mg therapy demonstrated statistically substantial and clinically meaningful progress compared to Avonex.

Leading multiple sclerosis drugs include Sanofi’s (SNY) Aubagio; Biogen’s (BIIB) Fampyra, Tecfidera, and Tysabri; Novartis’s (NVS) Gilenya; Teva Pharmaceuticals’ Copaxone; and Merck’s Rebif. The iShares Core S&P 500 ETF (IVV) invests ~0.50% of its total portfolio holdings in Celgene.

X

Please select a profession that best describes you: